Troponin T and N-terminal pro brain natriuretic peptide are potential markers of cardiac injury that are often measured in the inpatient setting. Can these markers be used in the outpatient setting to predict risk of developing ESRD in patients with diabetic kidney disease? Check it out in an exclusive interview on eAJKD.
Ref:
http://ajkdblog.org/2011/11/29/cardiac-biomarkers-in-ckd-and-esrd-what-to-make-of-them/
Wednesday, November 30, 2011
Tuesday, November 29, 2011
CONSULT ROUNDS: Sjogren's Syndrome and Glomerular Diseases?
What is the association of Sjogren's Syndrome(SS) with any glomerular disease..
Well,
besides few cases reports scattered in the literature, there are two large case
series that highlight this nicely.
In 2001,
Bossini et al described the clinical and morphological features of kidney
involvement in SS. Sixteen patients (27%) had laboratory evidence of
tubular and/or glomerular dysfunction. Renal biopsies from nine patients
showed tubulo‐interstitial nephritis in six and glomerular disease in
three. The three diagnosis were MPGN, mesangiproliferative and membranous.
Patients with renal involvement had a significantly shorter disease duration
compared with patients without renal abnormalities.
A more
recent study in CJASN looked at more number of patients and at least 24
biopsies of SS patients showing mostly tubular interstitial disease but the
glomerular disease was a mixed bag: FSGS, mild mesangial sclerosis, MPGN,
minimal change disease( 1 case), membranous, were the ones reported. The paper
is free access ( look below). Four patients (17%) were diagnosed with
lymphoma during their follow-up. Below is a pie chart from the paper that had
24 cases and the distribution on the biopsy. Overall, not a very common thing
to see in SS, but glomerular disease is likely.
Labels:
Consult Rounds,
glomerular diseases,
sjogrens
Monday, November 28, 2011
Access educational Tool
The AV fistula first website has developed some really good teaching resources for fistula and graft management and access care. The videos that are very educational and helpful are the link below:
have a look:
http://www.fistulafirst.org/HealthcareProfessionals/FFBIChangeConcepts/ChangeConcept9.aspx
Saturday, November 26, 2011
Friday, November 25, 2011
Complement Component Quiz Answers
Question:
Match the following complement components with their function in the complement cascade
C5a
|
Membrane attack complex
|
DAF
|
Initiates the alternative complement pathway
|
C5b-9
|
Initiates the classical complement pathway
|
Factor H
|
Byproduct of the classical complement pathway
|
C5
|
Potent inflammatory mediator
|
C1q
|
Membrane bound complement regulatory protein
|
C4d
|
Blockade of this complement component is the treatment for PNF
|
C3b
|
Deficiency results in atypical HUS
|
Answers:
C5a – Potent inflammatory mediator
DAF (decay accelerating factor) – membrane bound complement
regulatory protein
C5b-9 – membrane attack complex (MAC)
Factor H – Deficiency results in atypical HUS (hemolytic
uremic syndrome)
C5 - Blockade of this complement component is the treatment
for PNF (paroxysmal nocturnal hematuria)
C1q – Initiates the classical complement pathway
C4d - Byproduct of the classical complement pathway
C3b - Initiates the alternative complement pathway
Post by
Vinay Nair
Labels:
Clinical Case,
complements,
kidney transplantation,
quiz
Thursday, November 24, 2011
eAJKD: Pemetrexed Nephrotoxicity
Pemetrexed is an antifolate agent approved for the treatment of advanced lung cancer.A recent publication in American Journal of Kidney Diseases discusses potential nephrotoxicity of this drug. Kidney biopsy specimens showed tubulointerstitial injury with tubular simplification, shrinkage, loss of brush border, and tubular atrophy in a more advanced case. eAJKD did an exclusive video blog with the authors Dr. Ilya Glezerman( Renal service, Memorial Sloan Kettering Cancer Center, NY) and Dr.Surya Seshan( Chief of Renal Pathology, Professor of Pathology, Weill Cornell Medical Center, NY)
Check it out
http://ajkdblog.org/2011/11/23/pemetrexed-nephrotoxicity/
Check it out
http://ajkdblog.org/2011/11/23/pemetrexed-nephrotoxicity/
Labels:
drug toxicities,
eajkd,
Medications,
onco nephrology,
pemetrexed
Wednesday, November 23, 2011
Clinical case 47: Answers and Summary
WHICH OF THE FOLLOWING ELECTROLYTE ABNORMALITIES HAS BEEN ASSOCIATED WITH PARAPROTEINS?
Paraproteins may cause abnormal laboratory findings in 3 ways: 1) through the disease
process itself; 2) by interacting with the target of an assay; 3) by creating spurious results due to their
interference with the assay method. Paraproteins have been shown to cause interference with the
assays of multiple laboratory tests, including blood counts, sodium, calcium, phosphorus, lipids,
coagulation profiles, iron studies, blood urea nitrogen, creatinine, bilirubin, c-reactive protein,
glucose, uric acid, lactate dehydrogenase, alkaline phosphatase.
All the above listed findings have been described with paraproteins except the hypermagnesemia. Obviously, the most commonly discussed on board questions is pseudohyponatremia but that we don't see that often. Given the burden of light chains, usually one now encounters the others. See the references below for full primary data on these. IgM, given its size, is usually the big culprit but igG and igA have also been described. Paraproteins exert biphasic interference on serum phosphate levels, usually resulting in factitious hyperphosphatemia but occasionally in hypophosphatemia. Pseudohyperphosphatemia may be seen in patients with IgM, IgA, or IgG paraproteins. In addition, hypophosphatemic patients showing falsely “high” levels of phosphate may be labeled as pseudonormophosphatemic, and this may be just as clinically relevant as pseudohyperphosphatemia. Deproteination can usually correct this artifact.
Previous SectionNext Section
Previous Section
Next Section
Ref:
http://www.ncbi.nlm.nih.gov/pubmed/20118906
http://www.ncbi.nlm.nih.gov/pubmed/18251580
http://www.ncbi.nlm.nih.gov/pubmed/21849226
http://www.ncbi.nlm.nih.gov/pubmed/19141380
Subscribe to:
Posts (Atom)
